Wealth On Health

U.S. Senate Finance Committee requesting in July 2008 that the APA provide accounts for all of its pharmaceutical funding. Despite its announcement, within two months, the APA accepted more than $1.7 million in pharmaceutical company funds for its annual conference, held in San Francisco. Not surprising. In 2002, the APA’s Anand Pandya said that without pharmaceutical industry funds, membership dues could escalate 455% from $540 a year to $3,000. Pandya is president of the National Alliance on Mental Illness (NAMI), which in 2009 was also asked to provide records of its pharmaceutical company funding to federal investigators. About 56% of its $12 million-a-year income comes from drug makers (more below). Within a month of the APA’s announcement, its conflicts came under criticism again with the release of a study that found that 18 of the 20 members overseeing the revision of clinical guidelines for treating just three “mental disorders” had financial ties to drug companies. The common diagnoses generate some $25 billion a year in pharmaceutical sales. … Read ahead

Source: cchrint.org

Latest at cchrint.org

• Now Psychiatrists Want to Repackage Grief as a “mental disorder”
• The Irish Times—All in our heads: Have we taken psychiatry too far?
• US Department of Justice Probes Corruption in Big Pharma; Glaxo, Pfizer, Bristol-Myers Squibb, Eli Lilly & Merck
• Overmedication contributes to military suicides, advocates say
• WW market for antipsychotics to reach $20.8 bil—hence the heavy PR/marketing of ‘schizophrenia’—its a lucrative market
• The Hidden Tragedy of the CIA’s Experiments on Children
• Following 7-year-old’s psychiatric drug-induced suicide—Florida bans foster children from clinical drug trials